Cryoport (CYRX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Six directors are nominated for election at the annual meeting scheduled for June 5, 2026.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2026 is proposed.
Advisory approval of executive compensation for named executive officers is on the agenda.
Amendment to the 2018 Omnibus Equity Incentive Plan to increase authorized shares from 10,350,000 to 14,625,000 is proposed.
Other business may be transacted as may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Six individuals are nominated for board positions, including Linda Baddour, Daniel Hancock, Robert Hariri, Ram M. Jagannath, Ramkumar Mandalam, and Jerrell W. Shelton.
Executive compensation and say-on-pay
Shareholders are asked to approve, on an advisory basis, the compensation of named executive officers as disclosed in the proxy statement.
Latest events from Cryoport
- Q1 2026 revenue up 16–16.5%, guidance raised, and profitability expected in H2 2026.CYRX
Q1 20265 May 2026 - Strong revenue growth, digital transformation, and key governance votes mark this year's proxy.CYRX
Proxy filing23 Apr 2026 - FY2025 revenue rose 12% to $176.2M, exceeding guidance, with strong CGT and services growth.CYRX
Q4 202529 Mar 2026 - Q3 2024 saw service growth, margin gains, and reaffirmed guidance despite product softness.CYRX
Q3 202414 Mar 2026 - Q2 2024 revenue hit $57.6M, with 51% cell/gene therapy growth and a $63.8M impairment loss.CYRX
Q2 202414 Mar 2026 - 2024 revenue hit $228.4M, Q4 margin rose to 45.8%, and 2025 guidance is $240–$250M with EBITDA positivity.CYRX
Q4 202414 Mar 2026 - Q1 2025 revenue up 10%; DHL deal and CRYOPDP sale to boost global reach and liquidity.CYRX
Q1 202514 Mar 2026 - DHL acquires CRYOPDP for $195M, boosting growth, margins, and global reach in cell and gene therapy.CYRX
Investor Update26 Dec 2025 - Cost-cutting, innovation, and ESG focus drive growth as shareholders vote on key governance matters.CYRX
Proxy Filing2 Dec 2025